User profiles for A. van Sighem
 | Ard van SighemVerified email at amsterdamumc.nl Cited by 13979 |
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005
…, A McDonald, J Casabona, A van Sighem… - Annals of …, 2009 - Elsevier
PURPOSE: To describe and contextualize changes in rates of human immunodeficiency
virus (HIV) notifications in men who have sex with men (MSM) in eight countries (Australia, …
virus (HIV) notifications in men who have sex with men (MSM) in eight countries (Australia, …
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals
A van Sighem, L Gras, P Reiss, K Brinkman, F de Wolf - Aids, 2010 - journals.lww.com
Objective: To compare life expectancies between recently diagnosed HIV-infected patients
and age and sex-matched uninfected individuals from the general population. Design: …
and age and sex-matched uninfected individuals from the general population. Design: …
[HTML][HTML] Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Background Health care for people living with HIV has improved substantially in the past
two decades. Robust estimates of how these improvements have affected prognosis and life …
two decades. Robust estimates of how these improvements have affected prognosis and life …
[HTML][HTML] Future challenges for clinical care of an ageing population infected with HIV: a modelling study
…, C Smit, K Thyagarajan, A van Sighem… - The Lancet infectious …, 2015 - thelancet.com
Background The population infected with HIV is getting older and these people will increasingly
develop age-related non-communicable diseases (NCDs). We aimed to quantify the …
develop age-related non-communicable diseases (NCDs). We aimed to quantify the …
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
…, AM Kesselring, JT Griffin, AI Van Sighem… - JAIDS Journal of …, 2007 - journals.lww.com
Objective: CD4 cell count changes in therapy-naive patients were investigated during 7 years
of highly active antiretroviral therapy (HAART) in an observational cohort. Methods: Three …
of highly active antiretroviral therapy (HAART) in an observational cohort. Methods: Three …
Long-term mortality in HIV-positive individuals virally suppressed for> 3 years with incomplete CD4 recovery
…, J del Amo, A Van Sighem… - Clinical infectious …, 2014 - academic.oup.com
Background. Some human immunodeficiency virus (HIV)–infected individuals initiating
combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not …
combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not …
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
…, R Thiébaut, H Castro, AI Van Sighem… - The Lancet infectious …, 2011 - thelancet.com
Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …
Mortality and progression to AIDS after starting highly active antiretroviral therapy
Objectives: To examine survival and progression to AIDS among HIV-infected patients after
starting highly active antiretroviral therapy (HAART). Methods: The study population …
starting highly active antiretroviral therapy (HAART). Methods: The study population …
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort …
…, A Mocroft, JC Wasmuth, A van Sighem… - International journal …, 2012 - academic.oup.com
Background Using data from a large European collaborative study, we aimed to identify the
circumstances in which treated HIV-infected individuals will experience similar mortality rates …
circumstances in which treated HIV-infected individuals will experience similar mortality rates …
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
… van Sighem reports no disclosures relevant to the manuscript. J. Miro has received honoraria
for consultant and/or research grants from Abbott, Boehringer Ingelheim, BMS, Cubist, …
for consultant and/or research grants from Abbott, Boehringer Ingelheim, BMS, Cubist, …